BLUE BELL, Pa., May 13, 2021 /PRNewswire-PRWeb/ — Acumen Health HoldingsTM is proud to announce that it has acquired Ramard, Inc. into its portfolio of leading health product companies in order to ...

NEWTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic ...

Acumen and JCR aim to develop a product leveraging Acumen’s amyloid beta oligomer-selective antibody expertise and JCR’s transferrin-receptor-targeting blood-brain barrier-penetrating technology ...

Acumen Pharmaceuticals is developing an Alzheimer’s disease drug that it believes offers advantages compared to other approaches—including the recently approved Biogen therapy. A small clinical trial ...

Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain Delivery TM product candidate in early 2026 Expect to report topline results for ALTITUDE-AD, a Phase 2 study to ...

Healthcare leaders should enhance business acumen if they want to run successful practices without losing sight of the people ...

Acumen will present Phase 1 topline data on its Alzheimer’s therapeutic candidate, ACU193, at the annual Alzheimer’s Association International Conference. ACU193 is an anti-beta amyloid with a unique ...

Fintel reports that on June 17, 2025, Citigroup initiated coverage of Acumen Pharmaceuticals (NasdaqGS:ABOS) with a Buy recommendation. Analyst Price Forecast Suggests 682.89% Upside As of June 2, ...

BLUE BELL, Pa., June 17, 2021 /PRNewswire-PRWeb/ — Eye Love is one of the leading ocular products companies, with cutting-edge, medical products including lid and lash cleansers, heated eye masks, and ...

BLUE BELL, Pa., June 17, 2021 /PRNewswire-PRWeb/ — Eye Love is one of the leading ocular products companies, with cutting-edge, medical products including lid and lash cleansers, heated eye masks, and ...